Stock Taper
SCREENER COMPARE ANY 2 STOCKS
AGEN
AGENUS INC.
NASDAQ
$7.66
▼ DOWN 1.92% (-0.15)

KEY STATISTICS

Market Cap$318.98 M
52w High$8.85
52w Low$2.71
Dividend Yield—
Frequency—
P/E3.04
Volume740.36K
Shares Out.41.64M

COMPANY

LEADERSHIP

Garo H. Armen
CHIEF EXECUTIVE
Garo H. Armen

COMPENSATION 2026

Salary$715,260
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$64,909
Total$1,350,325

ABOUT

SECTOR
Healthcare
WENT PUBLIC
February 8, 2000
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
81

PRICE TARGET

Target High$25.00
Target Low$25.00
Target Median$25.00
Target Consensus$25.00

UPCOMING EARNINGS

DateNov 9, 2026
DayMonday
Rev. Est.$35.00M
NOV
9
MON

SPLIT RECORD

DATETYPERATIO
2024-04-12Reverse1:20
2023-04-26Forward1019:1000
2011-10-03Reverse1:6

PRICE

$7.66 ▼ DOWN 1.92% (−$0.15)
OVERLAYS
$7.65$7.80$7.95$8.109:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM7.66

About Agenus Inc.

https://www.agenusbio.com ↗

Agenus Inc. is a clinical-stage immuno-oncology company developing antibody platforms, vaccines, and immune checkpoint therapies, with multiple candidates in clinical trials and collaborations worldwide.

INDUSTRY

Biotechnology

A SERVICE AGENUS INC. IS KNOWN FOR

Botensilimab (BOT) and Balstilimab (BAL) combination therapy

Agenus's main asset is a next-generation immunotherapy platform combining Botensilimab (Fc-enhanced CTLA-4 inhibitor) and Balstilimab (PD-1 inhibitor), currently in late-stage clinical trials for various cancers.

COMPETITORS

COMPETITOR
AZN COMPARE
BMY COMPARE
BNTX COMPARE
INO COMPARE
MRK COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Non Cash Royalty Revenue$29.15M $31.05M ▲$29.14M ▼$28.15M ▼
Other$1.04M $0 ▼— —

Revenue by Geography

MapREGIONQ3-2025Q4-2025Q1-2026Q2-2026
UNITED STATES$30.23M $34.2M ▲$33.74M ▼$34.52M ▲
NonUS$1.04M $0 ▼— —

ETFS HOLDING THIS STOCK

ETFS HOLDING
48
LISTED HERE
8
RANKED BY POSITION SIZE
VTI
0.00% · 1.2M
XSU.TO
0.01% · 891.9K
FDM
0.53% · 182.8K
ZPRR.DE
0.01% · 48.4K
XRSU.L
0.01% · 36.4K
QQQS
1.08% · 32.0K
RSSL
0.01% · 18.9K
URTY
0.00% · 1.6K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
42.18%
HOLDERS
179
TOP 12 OF 179 · RANKED BY POSITION SIZE
Vanguard Group Inc
2.8M sh · $8.89M
Blackrock, Inc.
2.6M sh · $7.85M
Blackrock Fund Advisors
2.3M sh · $9.68M
Blackrock Institutional Trust Company, N.A.
2.1M sh · $8.6M
Blackrock Inc.
1.5M sh · $25.93M
Morgan Jess S & Co Inc
1.3M sh · $2.67M
Siren, L.L.C.
1.1M sh · $4.1M
Geode Capital Management, LLC
1.0M sh · $3.17M
B. Riley Financial, Inc.
757.0K sh · $2.07M
Mackenzie Financial Corp
714.2K sh · $2.19M
Marshall Wace, Llp
688.2K sh · $2.3M
Acadian Asset Management LLC
622.5K sh · $1.95M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets5
Debt To Equity1
Price To Earnings3
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR, OFFICER: SEE REMARKS
ARMEN GARO H
Purchase · 2.0M shares
2026-08-10
★
DIRECTOR
Corvese Brian
Purchase · 100.0K shares
2026-08-05
★
DIRECTOR
HARRISON THOMAS L
Purchase · 50.0K shares
2026-08-05
★
DIRECTOR
Hirsch Susan B
Purchase · 50.0K shares
2026-08-05

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
2 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY B. Riley Securities BUY

SECTORS PEERS

PEERPRICE
IRD$3.69COMPARE
TTRX$9.84COMPARE
FATE$2.43COMPARE
ZNTL$3.80COMPARE
ABOS$2.92COMPARE
HURA$2.11COMPARE
SEER$1.98COMPARE
INO$1.29COMPARE